Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry Pertinez

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Antimicrobial Agents and Chemotherapy|September 19, 2019
Re-growth of <i>Mycobacterium tuberculosis</i> populations exposed to antibiotic combinations is due to the presence of isoniazid and not bacterial growth rateCharlotte L Hendon-Dunn, Henry Pertinez, Alice A N Marriott, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 7, 2024
Population pharmacokinetic modeling of paired plasma-breast milk lamivudine data for estimation of infant exposure in breastfeeding mother-infant pairsFrancis Williams Ojara, Aida N Kawuma, Shadia Nakalema, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepineVincent L M Yip, Henry Pertinez, Xiaoli Meng, et al.
British Journal of Clinical Pharmacology|November 28, 2015
A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and childrenAlessandro Schipani, Henry Pertinez, Rachel Mlota, et al.
Biorxiv : the Preprint Server for Biology|February 10, 2021
Development of a highly sensitive bioanalytical assay for the quantification of favipiravirPaul Curley, Megan Neary, Usman Arshad, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2023
Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive TherapyYong S Chang, Si-Yang Li, Henry Pertinez, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2023
Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapyYong S Chang, Si-Yang Li, Henry Pertinez, et al.
Pharmacology Research & Perspectives|November 7, 2024
Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposureIng-Orn Prasanchaimontri, Weerawat Manosuthi, Henry Pertinez, et al.
Pharmaceutics|December 23, 2023
Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and HumansHannah Kinvig, Rajith K R Rajoli, Henry Pertinez, et al.
Tuberculosis (Edinburgh, Scotland)|June 15, 2017
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis modelGerjo J de Knegt, Laura Dickinson, Henry Pertinez, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Antimicrobial Agents and Chemotherapy|September 19, 2019
Re-growth of <i>Mycobacterium tuberculosis</i> populations exposed to antibiotic combinations is due to the presence of isoniazid and not bacterial growth rateCharlotte L Hendon-Dunn, Henry Pertinez, Alice A N Marriott, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 7, 2024
Population pharmacokinetic modeling of paired plasma-breast milk lamivudine data for estimation of infant exposure in breastfeeding mother-infant pairsFrancis Williams Ojara, Aida N Kawuma, Shadia Nakalema, et al.
British Journal of Clinical Pharmacology|November 20, 2020
Evaluation of clinical and genetic factors in the population pharmacokinetics of carbamazepineVincent L M Yip, Henry Pertinez, Xiaoli Meng, et al.
British Journal of Clinical Pharmacology|November 28, 2015
A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and childrenAlessandro Schipani, Henry Pertinez, Rachel Mlota, et al.
Biorxiv : the Preprint Server for Biology|February 10, 2021
Development of a highly sensitive bioanalytical assay for the quantification of favipiravirPaul Curley, Megan Neary, Usman Arshad, et al.
Antimicrobial Agents and Chemotherapy|June 20, 2023
Using Dynamic Oral Dosing of Rifapentine and Rifabutin to Simulate Exposure Profiles of Long-Acting Formulations in a Mouse Model of Tuberculosis Preventive TherapyYong S Chang, Si-Yang Li, Henry Pertinez, et al.
Biorxiv : the Preprint Server for Biology|April 24, 2023
Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapyYong S Chang, Si-Yang Li, Henry Pertinez, et al.
Pharmacology Research & Perspectives|November 7, 2024
Favipiravir pharmacokinetics in Thai adults with mild COVID-19: A sub-study of interpatient variability and ethnic differences in exposureIng-Orn Prasanchaimontri, Weerawat Manosuthi, Henry Pertinez, et al.
Pharmaceutics|December 23, 2023
Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and HumansHannah Kinvig, Rajith K R Rajoli, Henry Pertinez, et al.
Tuberculosis (Edinburgh, Scotland)|June 15, 2017
Assessment of treatment response by colony forming units, time to culture positivity and the molecular bacterial load assay compared in a mouse tuberculosis modelGerjo J de Knegt, Laura Dickinson, Henry Pertinez, et al.
Pageof 5